Anthony M. Magliocco

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

Jeffrey D. Bradley, Rebecca Paulus, Ritsuko Komaki et al. · The Lancet Oncology · 2015 · 2K citations · Full text

Consolidation Carboplatin, Oncology, Radiation Therapy +6

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer

Jeffrey D. Bradley, Chen Hu, Ritsuko Komaki et al. · Journal of Clinical Oncology · 2019 · 540 citations · Full text

Dose-Response Association of CD8⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Ellen L. Goode, Matthew S. Block, Kimberly R. Kalli et al. · JAMA Oncology · 2017 · 388 citations · Full text

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

Scott Kopetz, Katherine A. Guthrie, Van K. Morris et al. · Journal of Clinical Oncology · 2020 · 381 citations · Full text

Identification of nine new susceptibility loci for endometrial cancer

Tracy A. O’Mara, Dylan M. Glubb, Frédéric Amant et al. · Nature Communications · 2018 · 315 citations · Full text